Primary Hyperparathyroidism Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H2 2017
LONDON, Oct. 25, 2017 /PRNewswire/ -- Primary Hyperparathyroidism clinical trials report from VPA Research provides comprehensive analysis and trends in global Primary Hyperparathyroidism disease clinical trials. The research work analyzes the evolution of Primary Hyperparathyroidism clinical trial trends across countries and regions.
Download the full report: https://www.reportbuyer.com/product/5158747
The report focuses on drugs and therapies being evaluated for Primary Hyperparathyroidism treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.
Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Primary Hyperparathyroidism clinical trials.
Major drugs under development in Primary Hyperparathyroidism are provided in the report along with their details of Mechanism of Action, Route of Administration, Target, therapy, molecule and class.
Scope of the Report-
- Number of Primary Hyperparathyroidism clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas
- Trial information by Phase and Subjects recruited
- Trial information by status, type, sponsor type
- Drugs used for treatment of Primary Hyperparathyroidism
- Both observational and interventional trials analyzed
- Success rates of trials are analyzed
- Trends in enrollment over the past ten years identified
- Leading sponsors of Primary Hyperparathyroidism clinical trials worldwide are listed
Reasons to Buy-
- Track competition and design competitive advantages
- Identify right partners to associate with for further research
- Evaluate potential opportunities available in further clinical trials of the disease
- Formulate business development strategies through success rates of clinical trials
- Identify quick markets for recruiting subjects based on trials count by each market
Executive Summary
Of the four thyroid glands, at least one gland produces more than normal volume of parathyroid hormones. Though the root cause is unknown, hyperparathyroidism occurs when the gland enlarges. This leads to abnormal volume of phosphorous, calcium and vitamin D to move from bones into the blood. Classic symptoms include patients feel tired, irritable and achy, kidney stones, abdominal pain, bone pain and muscle aches. Typically, high calcium levels in blood are diagnosed. Hyperparathyroidism can lead to other medical conditions such as osteoporosis, pancreatic and renal failure.
Types-
- Primary Hyperparathyroidism
- Secondary Hyperparathyroidism
Primary hyperparathyroidism is caused by over stimulation of a normal number of parathyroid cells, the enlarged thyroid gland is removed through surgery in severe cases and in moderate cases, calcium and Vitamin D supplements are suggested.
Secondary hyperparathyroidism on the other hand, develops in response to renal dysfunction, abnormal phosphate levels and Vitamin D. To regulate these functions, high volume of PTH hormones and parathyroid hyperplasia are secreted.
Drugs in Primary Hyperparathyroidism clinical trials-
Amiloride
Cholecalciferol
Cinacalcet
Denosumab
Eplerenone
Evocalcet
Stamicis
Strontium Ranelate
Download the full report: https://www.reportbuyer.com/product/5158747
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
https://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article